{"id":340102,"date":"2025-08-20T10:19:59","date_gmt":"2025-08-20T10:19:59","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-intellia-therapeutics\/"},"modified":"2025-08-20T10:19:59","modified_gmt":"2025-08-20T10:19:59","slug":"how-to-buy-intellia-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/","title":{"rendered":"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-340102","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Intellia Therapeutics (NTLA) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, 2025 tahminleri ve gen d\u00fczenleme f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Intellia Therapeutics (NTLA) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131, g\u00fcncel fiyat analizi, 2025 tahminleri ve gen d\u00fczenleme f\u0131rsatlar\u0131 i\u00e7in ad\u0131m ad\u0131m sat\u0131n alma talimatlar\u0131 ile \u00f6\u011frenin."},"intro":"T\u0131bb\u0131n gelece\u011finin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. Intellia Therapeutics, genetik hastal\u0131klar\u0131 potansiyel olarak tedavi etmek i\u00e7in CRISPR teknolojisini kullanan gen d\u00fczenleme devriminin \u00f6n saflar\u0131nda yer al\u0131yor. Bu sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil\u2014sa\u011fl\u0131k hizmetlerini sonsuza dek de\u011fi\u015ftirebilecek bir teknolojiye yat\u0131r\u0131m yapma \u015fans\u0131d\u0131r. Bu \u00e7\u0131\u011f\u0131r a\u00e7an yolculu\u011fun bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"T\u0131bb\u0131n gelece\u011finin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. Intellia Therapeutics, genetik hastal\u0131klar\u0131 potansiyel olarak tedavi etmek i\u00e7in CRISPR teknolojisini kullanan gen d\u00fczenleme devriminin \u00f6n saflar\u0131nda yer al\u0131yor. Bu sadece ba\u015fka bir biyoteknoloji hissesi de\u011fil\u2014sa\u011fl\u0131k hizmetlerini sonsuza dek de\u011fi\u015ftirebilecek bir teknolojiye yat\u0131r\u0131m yapma \u015fans\u0131d\u0131r. Bu \u00e7\u0131\u011f\u0131r a\u00e7an yolculu\u011fun bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Ticaret Stratejisi<\/h2> <p>20 A\u011fustos 2025 itibar\u0131yla, Intellia Therapeutics (NTLA) <strong>10,21 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor ve bir\u00e7ok analistin volatil biyoteknoloji sekt\u00f6r\u00fcnde potansiyel bir al\u0131m f\u0131rsat\u0131 olarak g\u00f6rd\u00fc\u011f\u00fc bir durumu sunuyor. Hisse senedi son zamanlarda \u00f6nemli bask\u0131 ya\u015fad\u0131, ancak bu uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in cazip bir giri\u015f noktas\u0131 olabilir.<\/p> <p><strong>Takviminize not edin: 6 Kas\u0131m 2025<\/strong>, Intellia'n\u0131n 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayaca\u011f\u0131 bir sonraki kritik tarih. Tarihsel olarak, bu raporlar hisse senedini dramatik \u015fekilde hareket ettirdi. 7 A\u011fustos 2025 tarihli 2. \u00e7eyrek kazan\u00e7lar\u0131na bak\u0131ld\u0131\u011f\u0131nda, \u015firket i\u015f birli\u011fi gelirlerinde <strong>%106<\/strong> art\u0131\u015fla 14,2 milyon $ bildirdi ve analist beklentilerini a\u015ft\u0131<a href=\"https:\/\/www.aol.com\/finance\/intellia-ntla-q2-revenue-jumps-152350711.html\">AOL Finance<\/a>.<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><th>S\u00fcre<\/th><\/tr> <\/thead> <tbody> <tr><td>7 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>11,37 $<\/td><td>+%0,9 (1 g\u00fcn)<\/td><td>H\u0131zl\u0131 stabilizasyon<\/td><\/tr> <tr><td>8 May 2025<\/td><td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td><td>12,50 $<\/td><td>-%8,4<\/td><td>Haftalarca d\u00fc\u015f\u00fc\u015f<\/td><\/tr> <tr><td>6 \u015eub 2025<\/td><td>Y\u0131ll\u0131k Rapor<\/td><td>14,20 $<\/td><td>+%3,5<\/td><td>3 g\u00fcnl\u00fck y\u00fckseli\u015f<\/td><\/tr> <tr><td>7 Kas 2024<\/td><td>Ortakl\u0131k Haberi<\/td><td>15,80 $<\/td><td>+%6,2<\/td><td>S\u00fcrekli b\u00fcy\u00fcme<\/td><\/tr> <tr><td>8 A\u011fu 2024<\/td><td>2. \u00c7eyrek 2024<\/td><td>16,40 $<\/td><td>-%4,8<\/td><td>Ay s\u00fcren toparlanma<\/td><\/tr> <tr><td>9 May 2024<\/td><td>Klinik Veri<\/td><td>18,10 $<\/td><td>+%9,1<\/td><td>Yeni zirveler<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif klinik veriler ve ortakl\u0131k duyurular\u0131 genellikle sadece kazan\u00e7 raporlar\u0131ndan daha g\u00fc\u00e7l\u00fc y\u00fckseli\u015fler sa\u011flar. En \u00f6nemli hareketler, \u015firketin \u00e7\u0131\u011f\u0131r a\u00e7an klinik sonu\u00e7lar veya b\u00fcy\u00fck i\u015f birlikleri a\u00e7\u0131klad\u0131\u011f\u0131 zaman ger\u00e7ekle\u015fir.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h2> <p>Intellia'n\u0131n hissesi \u015eubat'tan A\u011fustos 2025'e kadar olduk\u00e7a hareketli bir yolculuk ya\u015fad\u0131:<\/p> <p><strong>\u015eubat 2025<\/strong>: G\u00fc\u00e7l\u00fc y\u0131ll\u0131k sonu\u00e7lar\u0131n ard\u0131ndan yakla\u015f\u0131k 14,20 $ seviyesinde i\u015flem g\u00f6rd\u00fc<br\/> <strong>Mart 2025<\/strong>: Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k nedeniyle 12,80 $ seviyesine d\u00fc\u015ft\u00fc<br\/> <strong>Nisan 2025<\/strong>: Pozitif klinik g\u00fcncellemelerle 13,50 $ seviyesine toparland\u0131<br\/> <strong>May\u0131s 2025<\/strong>: 1. \u00e7eyrek kazan\u00e7 hayal k\u0131r\u0131kl\u0131\u011f\u0131n\u0131n ard\u0131ndan 11,40 $ seviyesine geriledi<br\/> <strong>Haziran 2025<\/strong>: 12,00 $ civar\u0131nda stabilizasyon sa\u011flad\u0131<br\/> <strong>Temmuz 2025<\/strong>: Yenilenen yat\u0131r\u0131mc\u0131 ilgisiyle 13,19 $ seviyesine y\u00fckseldi<br\/> <strong>A\u011fustos 2025<\/strong>: \u015eu an 10,21 $ seviyelerine geri \u00e7ekilme ya\u015fan\u0131yor<\/p> <p><strong>%17'lik d\u00fc\u015f\u00fc\u015f<\/strong> alt\u0131 ayda endi\u015fe verici g\u00f6r\u00fcnebilir, ancak ba\u011flam\u0131 anlamak \u00f6nemlidir. \u00d6zellikle klinik a\u015famadaki biyoteknoloji hisseleri, klinik deneme sonu\u00e7lar\u0131, d\u00fczenleyici g\u00fcncellemeler ve riskli varl\u0131klara y\u00f6nelik piyasa duyarl\u0131l\u0131\u011f\u0131na ba\u011fl\u0131 olarak y\u00fcksek volatilite ya\u015far.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 B\u00fcy\u00fcme Y\u00f6r\u00fcngesi<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak, gelecekte neler olabilece\u011fi:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 16-18 $ aral\u0131\u011f\u0131 (mevcut fiyattan %57-76 art\u0131\u015f)<br\/> <em>Gerek\u00e7e: Pozitif 3. ve 4. \u00e7eyrek kazan\u00e7 ivmesi ve klinik ilerleme<\/em><\/p> <p><strong>2026 Hedefi<\/strong>: 22-25 $ (potansiyel %115-145 b\u00fcy\u00fcme)<br\/> <em>Kataliz\u00f6r: Faz 3 veri sonu\u00e7lar\u0131 ve BLA ba\u015fvuru haz\u0131rl\u0131\u011f\u0131<\/em><\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 35-45 $ (%243-341 de\u011fer art\u0131\u015f\u0131)<br\/> <em>\u0130tici G\u00fc\u00e7: Potansiyel ilk ticari lansmanlar ve geni\u015fletilmi\u015f \u00fcr\u00fcn hatt\u0131<\/em><\/p> <p><strong>2030 Vizyonu<\/strong>: 50-65 $ (%390-537 uzun vadeli getiri)<br\/> <em>Temel: Birden fazla onaylanm\u0131\u015f terapi ve pazar geni\u015flemesi<\/em><\/p> <p><strong>Karar<\/strong>: Risk tolerans\u0131 olan uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Mevcut fiyat, gen d\u00fczenleme terapileri onay al\u0131rsa nesiller boyu hat\u0131rlanacak bir al\u0131m f\u0131rsat\u0131n\u0131 temsil ediyor olabilir.<\/p> <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Biyoteknoloji Volatilitesinde Yol Alma<\/h2> <h3>Olas\u0131 Dezavantajlar<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: \u0130la\u00e7 adaylar\u0131n\u0131n %90'\u0131 ba\u015far\u0131s\u0131z olur - biyoteknolojide ger\u00e7ek bir durum<\/li> <li><strong>D\u00fczenleyici Engeller<\/strong>: FDA onaylar\u0131 asla garanti de\u011fildir, \u00f6zellikle yeni teknolojiler i\u00e7in<\/li> <li><strong>Nakit T\u00fcketimi Endi\u015feleri<\/strong>: 630,5 milyon $ nakit pozisyonuna ra\u011fmen<a href=\"https:\/\/www.stocktitan.net\/news\/NTLA\/intellia-therapeutics-announces-second-quarter-2025-financial-zqecci6852pr.html\">StockTitan<\/a>, y\u00fcksek Ar-Ge maliyetleri devam ediyor<\/li> <li><strong>Piyasa Duyarl\u0131l\u0131\u011f\u0131<\/strong>: Biyoteknoloji sekt\u00f6r\u00fc genel yat\u0131r\u0131mc\u0131lar aras\u0131nda pop\u00fcler de\u011fil<\/li> <li><strong>Rekabet<\/strong>: CRISPR Therapeutics ve Editas Medicine gibi di\u011fer CRISPR \u015firketleri ilerliyor<\/li> <\/ul> <h3>2025 \u0130\u00e7in Pozitif Sinyaller<\/h3> <ul> <li><strong>Gelir B\u00fcy\u00fcmesi<\/strong>: %106 i\u015f birli\u011fi geliri art\u0131\u015f\u0131 ortakl\u0131k g\u00fcc\u00fcn\u00fc g\u00f6steriyor<a href=\"https:\/\/www.nasdaq.com\/articles\/intellia-ntla-q2-revenue-jumps-106\">Nasdaq<\/a><\/li> <li><strong>Klinik \u0130lerleme<\/strong>: Faz 3 denemeleri planlanandan daha h\u0131zl\u0131 ilerliyor<\/li> <li><strong>Kurumsal Destek<\/strong>: ARK Investment, 7,17 milyon $ de\u011ferinde 560.600 hisse sat\u0131n ald\u0131<a href=\"https:\/\/www.ainvest.com\/news\/cathie-wood-ark-investment-purchases-560k-shares-intellia-therapeutics-2508\/\">AInvest<\/a><\/li> <li><strong>Nakit Yolu<\/strong>: Operasyonlar\u0131 2027'nin ilk yar\u0131s\u0131na kadar finanse ederek istikrar sa\u011fl\u0131yor<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Gen d\u00fczenleme artan d\u00fczenleyici kabul g\u00f6r\u00fcyor<\/li> <\/ul> <h2>\ud83d\udcca Son Haberlerin Etki Analizi<\/h2> <p>7 A\u011fustos 2025 tarihli 2. \u00e7eyrek kazan\u00e7lar\u0131, piyasa taraf\u0131ndan hen\u00fcz tam olarak takdir edilmemi\u015f birka\u00e7 olumlu veri noktas\u0131 sa\u011flad\u0131:<\/p> <ul> <li><strong>Mali G\u00fc\u00e7<\/strong>: 630,5 milyon $ nakit pozisyonu k\u0131sa vadeli seyrelme korkular\u0131n\u0131 ortadan kald\u0131r\u0131yor<\/li> <li><strong>Gelir A\u015f\u0131m\u0131<\/strong>: Beklenen 11,9 milyon $ kar\u015f\u0131s\u0131nda 14,2 milyon $ ortakl\u0131k de\u011ferini g\u00f6steriyor<\/li> <li><strong>Klinik H\u0131zlanma<\/strong>: Faz 3 denemeleri beklenenden daha h\u0131zl\u0131 ilerliyor<\/li> <li><strong>Verimlilik \u0130yile\u015ftirmeleri<\/strong>: Yeniden yap\u0131land\u0131rma tamamland\u0131, kaynaklar \u00f6nc\u00fc programlara odaklan\u0131yor<\/li> <\/ul> <p>Piyasan\u0131n mutedil tepkisi muhtemelen \u015firket \u00f6zelinden ziyade daha geni\u015f biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131\u011f\u0131 yans\u0131t\u0131yor. Bu, se\u00e7ici yat\u0131r\u0131mc\u0131lar i\u00e7in potansiyel bir f\u0131rsat yarat\u0131yor.<\/p> <h2>\ud83c\udfaf Yeni Ba\u015flayan T\u00fcccar \u0130\u00e7in Bug\u00fcnk\u00fc Eylem Plan\u0131<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-5'ini y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131r\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: T\u00fcm\u00fcn\u00fc bir kerede de\u011fil, ayl\u0131k 500 $ gibi taksitlerle sat\u0131n al\u0131n<\/li> <li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: Stratejik giri\u015fler i\u00e7in 9,50 $, 11,00 $ ve 13,00 $ seviyelerinde bildirimler<\/li> <li><strong>Uzun Vadeli D\u00fc\u015f\u00fcnce<\/strong>: Klinik geli\u015fmeler i\u00e7in en az 3-5 y\u0131l tutmay\u0131 planlay\u0131n<\/li> <li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: \"NTLA ticareti, boya kurumas\u0131n\u0131 izlemek gibidir... e\u011fer boya aniden hastal\u0131klar\u0131 iyile\u015ftirip sizi bir gecede zengin edebilirse. Sab\u0131r gereklidir!\"<\/li> <\/ol> <h2>\u2705 Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ listeleri ve kesirli hisse sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap Kurulumunu Tamamlay\u0131n<\/td><td>Kimlik ve finansman bilgilerini sa\u011flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>Fon Yat\u0131r\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"NTLA\" Aramas\u0131 Yap\u0131n<\/td><td>Do\u011fru sonu\u00e7lar i\u00e7in sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Sipari\u015f T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>6<\/td><td>Sipari\u015f Detaylar\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td><td>Komisyon \u00fccretleri ve takas tarihlerini kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Sat\u0131n Alma \u0130\u015flemini Ger\u00e7ekle\u015ftirin<\/td><td>Sipari\u015fi onaylay\u0131n ve y\u00fcr\u00fctmeyi izleyin<\/td><\/tr> <tr><td>8<\/td><td>Portf\u00f6y Takibi Kurun<\/td><td>Fiyat uyar\u0131lar\u0131 ve performans takibi olu\u015fturun<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, NTLA gibi pozisyonlara giri\u015f yapmay\u0131 daha eri\u015filebilir k\u0131lan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile stratejileri d\u00fc\u015f\u00fck riskle test edin<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek belge KYC s\u00fcreci h\u0131zl\u0131 hesap aktivasyonu sa\u011flar<\/li> <li><strong>\u00c7e\u015fitli Fonlama<\/strong>: Y\u00fczlerce para yat\u0131rma ve \u00e7ekme y\u00f6ntemi esneklik sunar<\/li> <li><strong>Kesirli Hisseler<\/strong>: K\u0131smi hisse alabilme imkan\u0131 y\u00fcksek fiyatl\u0131 hisseleri eri\u015filebilir k\u0131lar<\/li> <li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: <a href=\"\/blog\">Pocket Option blogu<\/a> s\u00fcrekli \u00f6\u011frenme f\u0131rsatlar\u0131 sunar<\/li> <\/ul> <p>Bu \u00f6zellikler, pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ve risk y\u00f6netiminin kritik oldu\u011fu volatil sekt\u00f6rlerde, \u00f6zellikle biyoteknolojide yat\u0131r\u0131m yaparken \u00e7ok de\u011ferlidir.<\/p> <h2>\ud83e\uddec 2025'te Intellia Therapeutics: Gen D\u00fczenleme \u00d6nc\u00fcs\u00fc<\/h2> <p>Intellia, genetik hastal\u0131klar\u0131 ele al\u0131\u015f \u015feklimizi devrim niteli\u011finde de\u011fi\u015ftirebilecek tedaviler geli\u015ftiren CRISPR tabanl\u0131 terapilerde lider konumdad\u0131r. \u015eirketin hem in vivo (v\u00fccut i\u00e7i) hem de ex vivo (v\u00fccut d\u0131\u015f\u0131) yakla\u015f\u0131mlara odaklanmas\u0131, onlar\u0131 gen d\u00fczenleme alan\u0131nda benzersiz k\u0131lar<a href=\"https:\/\/crisprmedicinenews.com\/company\/card\/intellia-therapeutics\/\">CRISPR Medicine News<\/a>.<\/p> <p>En geli\u015fmi\u015f programlar\u0131, d\u00fcnya \u00e7ap\u0131nda binlerce hastay\u0131 etkileyen kal\u0131tsal anjiyo\u00f6dem ve transtiretin amiloidozu hedeflemektedir - s\u0131n\u0131rl\u0131 tedavi se\u00e7enekleri olan hastal\u0131klar. 2025 ba\u015f\u0131nda yap\u0131lan yeniden yap\u0131land\u0131rma, %27 personel azalt\u0131m\u0131yla zorlay\u0131c\u0131 olsa da<a href=\"https:\/\/www.fiercebiotech.com\/biotech\/intellia-citing-challenging-market-environment-culls-27-staff-it-takes-ax-pipeline\">Fierce Biotech<\/a>, bu umut vadeden ge\u00e7 a\u015fama varl\u0131klara odaklanmay\u0131 g\u00fc\u00e7lendirdi.<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Intellia'n\u0131n Cambridge merkezinde, teknolojileriyle d\u00fczenlenen ve terap\u00f6tik at\u0131l\u0131mlara yol a\u00e7an DNA dizilerini g\u00f6steren bir \"CRISPR \u015e\u00f6hret Duvar\u0131\" bulunmaktad\u0131r - \u00e7al\u0131\u015fanlara genetik kodu hayat kurtarmak i\u00e7in kelimenin tam anlam\u0131yla yeniden yazd\u0131klar\u0131n\u0131 s\u00fcrekli hat\u0131rlatan bir simge.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Ticaret Stratejisi<\/h2>\n<p>20 A\u011fustos 2025 itibar\u0131yla, Intellia Therapeutics (NTLA) <strong>10,21 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor ve bir\u00e7ok analistin volatil biyoteknoloji sekt\u00f6r\u00fcnde potansiyel bir al\u0131m f\u0131rsat\u0131 olarak g\u00f6rd\u00fc\u011f\u00fc bir durumu sunuyor. Hisse senedi son zamanlarda \u00f6nemli bask\u0131 ya\u015fad\u0131, ancak bu uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in cazip bir giri\u015f noktas\u0131 olabilir.<\/p>\n<p><strong>Takviminize not edin: 6 Kas\u0131m 2025<\/strong>, Intellia&#8217;n\u0131n 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayaca\u011f\u0131 bir sonraki kritik tarih. Tarihsel olarak, bu raporlar hisse senedini dramatik \u015fekilde hareket ettirdi. 7 A\u011fustos 2025 tarihli 2. \u00e7eyrek kazan\u00e7lar\u0131na bak\u0131ld\u0131\u011f\u0131nda, \u015firket i\u015f birli\u011fi gelirlerinde <strong>%106<\/strong> art\u0131\u015fla 14,2 milyon $ bildirdi ve analist beklentilerini a\u015ft\u0131<a href=\"https:\/\/www.aol.com\/finance\/intellia-ntla-q2-revenue-jumps-152350711.html\">AOL Finance<\/a>.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<th>S\u00fcre<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>7 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>11,37 $<\/td>\n<td>+%0,9 (1 g\u00fcn)<\/td>\n<td>H\u0131zl\u0131 stabilizasyon<\/td>\n<\/tr>\n<tr>\n<td>8 May 2025<\/td>\n<td>1. \u00c7eyrek Sonu\u00e7lar\u0131<\/td>\n<td>12,50 $<\/td>\n<td>-%8,4<\/td>\n<td>Haftalarca d\u00fc\u015f\u00fc\u015f<\/td>\n<\/tr>\n<tr>\n<td>6 \u015eub 2025<\/td>\n<td>Y\u0131ll\u0131k Rapor<\/td>\n<td>14,20 $<\/td>\n<td>+%3,5<\/td>\n<td>3 g\u00fcnl\u00fck y\u00fckseli\u015f<\/td>\n<\/tr>\n<tr>\n<td>7 Kas 2024<\/td>\n<td>Ortakl\u0131k Haberi<\/td>\n<td>15,80 $<\/td>\n<td>+%6,2<\/td>\n<td>S\u00fcrekli b\u00fcy\u00fcme<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek 2024<\/td>\n<td>16,40 $<\/td>\n<td>-%4,8<\/td>\n<td>Ay s\u00fcren toparlanma<\/td>\n<\/tr>\n<tr>\n<td>9 May 2024<\/td>\n<td>Klinik Veri<\/td>\n<td>18,10 $<\/td>\n<td>+%9,1<\/td>\n<td>Yeni zirveler<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Pozitif klinik veriler ve ortakl\u0131k duyurular\u0131 genellikle sadece kazan\u00e7 raporlar\u0131ndan daha g\u00fc\u00e7l\u00fc y\u00fckseli\u015fler sa\u011flar. En \u00f6nemli hareketler, \u015firketin \u00e7\u0131\u011f\u0131r a\u00e7an klinik sonu\u00e7lar veya b\u00fcy\u00fck i\u015f birlikleri a\u00e7\u0131klad\u0131\u011f\u0131 zaman ger\u00e7ekle\u015fir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h2>\n<p>Intellia&#8217;n\u0131n hissesi \u015eubat&#8217;tan A\u011fustos 2025&#8217;e kadar olduk\u00e7a hareketli bir yolculuk ya\u015fad\u0131:<\/p>\n<p><strong>\u015eubat 2025<\/strong>: G\u00fc\u00e7l\u00fc y\u0131ll\u0131k sonu\u00e7lar\u0131n ard\u0131ndan yakla\u015f\u0131k 14,20 $ seviyesinde i\u015flem g\u00f6rd\u00fc<br \/> <strong>Mart 2025<\/strong>: Daha geni\u015f biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k nedeniyle 12,80 $ seviyesine d\u00fc\u015ft\u00fc<br \/> <strong>Nisan 2025<\/strong>: Pozitif klinik g\u00fcncellemelerle 13,50 $ seviyesine toparland\u0131<br \/> <strong>May\u0131s 2025<\/strong>: 1. \u00e7eyrek kazan\u00e7 hayal k\u0131r\u0131kl\u0131\u011f\u0131n\u0131n ard\u0131ndan 11,40 $ seviyesine geriledi<br \/> <strong>Haziran 2025<\/strong>: 12,00 $ civar\u0131nda stabilizasyon sa\u011flad\u0131<br \/> <strong>Temmuz 2025<\/strong>: Yenilenen yat\u0131r\u0131mc\u0131 ilgisiyle 13,19 $ seviyesine y\u00fckseldi<br \/> <strong>A\u011fustos 2025<\/strong>: \u015eu an 10,21 $ seviyelerine geri \u00e7ekilme ya\u015fan\u0131yor<\/p>\n<p><strong>%17&#8217;lik d\u00fc\u015f\u00fc\u015f<\/strong> alt\u0131 ayda endi\u015fe verici g\u00f6r\u00fcnebilir, ancak ba\u011flam\u0131 anlamak \u00f6nemlidir. \u00d6zellikle klinik a\u015famadaki biyoteknoloji hisseleri, klinik deneme sonu\u00e7lar\u0131, d\u00fczenleyici g\u00fcncellemeler ve riskli varl\u0131klara y\u00f6nelik piyasa duyarl\u0131l\u0131\u011f\u0131na ba\u011fl\u0131 olarak y\u00fcksek volatilite ya\u015far.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 B\u00fcy\u00fcme Y\u00f6r\u00fcngesi<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak, gelecekte neler olabilece\u011fi:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 16-18 $ aral\u0131\u011f\u0131 (mevcut fiyattan %57-76 art\u0131\u015f)<br \/> <em>Gerek\u00e7e: Pozitif 3. ve 4. \u00e7eyrek kazan\u00e7 ivmesi ve klinik ilerleme<\/em><\/p>\n<p><strong>2026 Hedefi<\/strong>: 22-25 $ (potansiyel %115-145 b\u00fcy\u00fcme)<br \/> <em>Kataliz\u00f6r: Faz 3 veri sonu\u00e7lar\u0131 ve BLA ba\u015fvuru haz\u0131rl\u0131\u011f\u0131<\/em><\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 35-45 $ (%243-341 de\u011fer art\u0131\u015f\u0131)<br \/> <em>\u0130tici G\u00fc\u00e7: Potansiyel ilk ticari lansmanlar ve geni\u015fletilmi\u015f \u00fcr\u00fcn hatt\u0131<\/em><\/p>\n<p><strong>2030 Vizyonu<\/strong>: 50-65 $ (%390-537 uzun vadeli getiri)<br \/> <em>Temel: Birden fazla onaylanm\u0131\u015f terapi ve pazar geni\u015flemesi<\/em><\/p>\n<p><strong>Karar<\/strong>: Risk tolerans\u0131 olan uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM. Mevcut fiyat, gen d\u00fczenleme terapileri onay al\u0131rsa nesiller boyu hat\u0131rlanacak bir al\u0131m f\u0131rsat\u0131n\u0131 temsil ediyor olabilir.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Biyoteknoloji Volatilitesinde Yol Alma<\/h2>\n<h3>Olas\u0131 Dezavantajlar<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: \u0130la\u00e7 adaylar\u0131n\u0131n %90&#8217;\u0131 ba\u015far\u0131s\u0131z olur &#8211; biyoteknolojide ger\u00e7ek bir durum<\/li>\n<li><strong>D\u00fczenleyici Engeller<\/strong>: FDA onaylar\u0131 asla garanti de\u011fildir, \u00f6zellikle yeni teknolojiler i\u00e7in<\/li>\n<li><strong>Nakit T\u00fcketimi Endi\u015feleri<\/strong>: 630,5 milyon $ nakit pozisyonuna ra\u011fmen<a href=\"https:\/\/www.stocktitan.net\/news\/NTLA\/intellia-therapeutics-announces-second-quarter-2025-financial-zqecci6852pr.html\">StockTitan<\/a>, y\u00fcksek Ar-Ge maliyetleri devam ediyor<\/li>\n<li><strong>Piyasa Duyarl\u0131l\u0131\u011f\u0131<\/strong>: Biyoteknoloji sekt\u00f6r\u00fc genel yat\u0131r\u0131mc\u0131lar aras\u0131nda pop\u00fcler de\u011fil<\/li>\n<li><strong>Rekabet<\/strong>: CRISPR Therapeutics ve Editas Medicine gibi di\u011fer CRISPR \u015firketleri ilerliyor<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Pozitif Sinyaller<\/h3>\n<ul>\n<li><strong>Gelir B\u00fcy\u00fcmesi<\/strong>: %106 i\u015f birli\u011fi geliri art\u0131\u015f\u0131 ortakl\u0131k g\u00fcc\u00fcn\u00fc g\u00f6steriyor<a href=\"https:\/\/www.nasdaq.com\/articles\/intellia-ntla-q2-revenue-jumps-106\">Nasdaq<\/a><\/li>\n<li><strong>Klinik \u0130lerleme<\/strong>: Faz 3 denemeleri planlanandan daha h\u0131zl\u0131 ilerliyor<\/li>\n<li><strong>Kurumsal Destek<\/strong>: ARK Investment, 7,17 milyon $ de\u011ferinde 560.600 hisse sat\u0131n ald\u0131<a href=\"https:\/\/www.ainvest.com\/news\/cathie-wood-ark-investment-purchases-560k-shares-intellia-therapeutics-2508\/\">AInvest<\/a><\/li>\n<li><strong>Nakit Yolu<\/strong>: Operasyonlar\u0131 2027&#8217;nin ilk yar\u0131s\u0131na kadar finanse ederek istikrar sa\u011fl\u0131yor<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Gen d\u00fczenleme artan d\u00fczenleyici kabul g\u00f6r\u00fcyor<\/li>\n<\/ul>\n<h2>\ud83d\udcca Son Haberlerin Etki Analizi<\/h2>\n<p>7 A\u011fustos 2025 tarihli 2. \u00e7eyrek kazan\u00e7lar\u0131, piyasa taraf\u0131ndan hen\u00fcz tam olarak takdir edilmemi\u015f birka\u00e7 olumlu veri noktas\u0131 sa\u011flad\u0131:<\/p>\n<ul>\n<li><strong>Mali G\u00fc\u00e7<\/strong>: 630,5 milyon $ nakit pozisyonu k\u0131sa vadeli seyrelme korkular\u0131n\u0131 ortadan kald\u0131r\u0131yor<\/li>\n<li><strong>Gelir A\u015f\u0131m\u0131<\/strong>: Beklenen 11,9 milyon $ kar\u015f\u0131s\u0131nda 14,2 milyon $ ortakl\u0131k de\u011ferini g\u00f6steriyor<\/li>\n<li><strong>Klinik H\u0131zlanma<\/strong>: Faz 3 denemeleri beklenenden daha h\u0131zl\u0131 ilerliyor<\/li>\n<li><strong>Verimlilik \u0130yile\u015ftirmeleri<\/strong>: Yeniden yap\u0131land\u0131rma tamamland\u0131, kaynaklar \u00f6nc\u00fc programlara odaklan\u0131yor<\/li>\n<\/ul>\n<p>Piyasan\u0131n mutedil tepkisi muhtemelen \u015firket \u00f6zelinden ziyade daha geni\u015f biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131\u011f\u0131 yans\u0131t\u0131yor. Bu, se\u00e7ici yat\u0131r\u0131mc\u0131lar i\u00e7in potansiyel bir f\u0131rsat yarat\u0131yor.<\/p>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan T\u00fcccar \u0130\u00e7in Bug\u00fcnk\u00fc Eylem Plan\u0131<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn sadece %2-5&#8217;ini y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131r\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: T\u00fcm\u00fcn\u00fc bir kerede de\u011fil, ayl\u0131k 500 $ gibi taksitlerle sat\u0131n al\u0131n<\/li>\n<li><strong>Fiyat Uyar\u0131lar\u0131 Kurun<\/strong>: Stratejik giri\u015fler i\u00e7in 9,50 $, 11,00 $ ve 13,00 $ seviyelerinde bildirimler<\/li>\n<li><strong>Uzun Vadeli D\u00fc\u015f\u00fcnce<\/strong>: Klinik geli\u015fmeler i\u00e7in en az 3-5 y\u0131l tutmay\u0131 planlay\u0131n<\/li>\n<li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: &#8220;NTLA ticareti, boya kurumas\u0131n\u0131 izlemek gibidir&#8230; e\u011fer boya aniden hastal\u0131klar\u0131 iyile\u015ftirip sizi bir gecede zengin edebilirse. Sab\u0131r gereklidir!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeleri ve kesirli hisse sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Kurulumunu Tamamlay\u0131n<\/td>\n<td>Kimlik ve finansman bilgilerini sa\u011flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon Yat\u0131r\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;NTLA&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>Do\u011fru sonu\u00e7lar i\u00e7in sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sipari\u015f T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Sipari\u015f Detaylar\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td>\n<td>Komisyon \u00fccretleri ve takas tarihlerini kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Sat\u0131n Alma \u0130\u015flemini Ger\u00e7ekle\u015ftirin<\/td>\n<td>Sipari\u015fi onaylay\u0131n ve y\u00fcr\u00fctmeyi izleyin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Portf\u00f6y Takibi Kurun<\/td>\n<td>Fiyat uyar\u0131lar\u0131 ve performans takibi olu\u015fturun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, NTLA gibi pozisyonlara giri\u015f yapmay\u0131 daha eri\u015filebilir k\u0131lan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile stratejileri d\u00fc\u015f\u00fck riskle test edin<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Tek belge KYC s\u00fcreci h\u0131zl\u0131 hesap aktivasyonu sa\u011flar<\/li>\n<li><strong>\u00c7e\u015fitli Fonlama<\/strong>: Y\u00fczlerce para yat\u0131rma ve \u00e7ekme y\u00f6ntemi esneklik sunar<\/li>\n<li><strong>Kesirli Hisseler<\/strong>: K\u0131smi hisse alabilme imkan\u0131 y\u00fcksek fiyatl\u0131 hisseleri eri\u015filebilir k\u0131lar<\/li>\n<li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: <a href=\"\/blog\">Pocket Option blogu<\/a> s\u00fcrekli \u00f6\u011frenme f\u0131rsatlar\u0131 sunar<\/li>\n<\/ul>\n<p>Bu \u00f6zellikler, pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ve risk y\u00f6netiminin kritik oldu\u011fu volatil sekt\u00f6rlerde, \u00f6zellikle biyoteknolojide yat\u0131r\u0131m yaparken \u00e7ok de\u011ferlidir.<\/p>\n<h2>\ud83e\uddec 2025&#8217;te Intellia Therapeutics: Gen D\u00fczenleme \u00d6nc\u00fcs\u00fc<\/h2>\n<p>Intellia, genetik hastal\u0131klar\u0131 ele al\u0131\u015f \u015feklimizi devrim niteli\u011finde de\u011fi\u015ftirebilecek tedaviler geli\u015ftiren CRISPR tabanl\u0131 terapilerde lider konumdad\u0131r. \u015eirketin hem in vivo (v\u00fccut i\u00e7i) hem de ex vivo (v\u00fccut d\u0131\u015f\u0131) yakla\u015f\u0131mlara odaklanmas\u0131, onlar\u0131 gen d\u00fczenleme alan\u0131nda benzersiz k\u0131lar<a href=\"https:\/\/crisprmedicinenews.com\/company\/card\/intellia-therapeutics\/\">CRISPR Medicine News<\/a>.<\/p>\n<p>En geli\u015fmi\u015f programlar\u0131, d\u00fcnya \u00e7ap\u0131nda binlerce hastay\u0131 etkileyen kal\u0131tsal anjiyo\u00f6dem ve transtiretin amiloidozu hedeflemektedir &#8211; s\u0131n\u0131rl\u0131 tedavi se\u00e7enekleri olan hastal\u0131klar. 2025 ba\u015f\u0131nda yap\u0131lan yeniden yap\u0131land\u0131rma, %27 personel azalt\u0131m\u0131yla zorlay\u0131c\u0131 olsa da<a href=\"https:\/\/www.fiercebiotech.com\/biotech\/intellia-citing-challenging-market-environment-culls-27-staff-it-takes-ax-pipeline\">Fierce Biotech<\/a>, bu umut vadeden ge\u00e7 a\u015fama varl\u0131klara odaklanmay\u0131 g\u00fc\u00e7lendirdi.<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Intellia&#8217;n\u0131n Cambridge merkezinde, teknolojileriyle d\u00fczenlenen ve terap\u00f6tik at\u0131l\u0131mlara yol a\u00e7an DNA dizilerini g\u00f6steren bir &#8220;CRISPR \u015e\u00f6hret Duvar\u0131&#8221; bulunmaktad\u0131r &#8211; \u00e7al\u0131\u015fanlara genetik kodu hayat kurtarmak i\u00e7in kelimenin tam anlam\u0131yla yeniden yazd\u0131klar\u0131n\u0131 s\u00fcrekli hat\u0131rlatan bir simge.<\/p>\n"},"faq":[{"question":"Intellia Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir arac\u0131 kurum veya ticaret platformu se\u00e7in, hesap a\u00e7\u0131n, fon yat\u0131r\u0131n, \"NTLA\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak hisse sat\u0131n al\u0131n ve portf\u00f6y\u00fcn\u00fcz\u00fc takip edin."},{"question":"Intellia Therapeutics hisseleri i\u00e7in riskler nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, d\u00fczenleyici onay engelleri, y\u00fcksek Ar-Ge maliyetleri, piyasa duyarl\u0131l\u0131\u011f\u0131 ve rekabet \u00f6nemli risk fakt\u00f6rleridir."},{"question":"Intellia Therapeutics'in 2025 sonras\u0131 fiyat tahmini nedir?","answer":"2025 sonunda 16-18 $, 2026'da 22-25 $, 2028'de 35-45 $ ve 2030'da 50-65 $ aral\u0131\u011f\u0131nda b\u00fcy\u00fcme beklenmektedir."},{"question":"Yeni ba\u015flayanlar i\u00e7in Intellia Therapeutics hissesi yat\u0131r\u0131m\u0131 \u00f6nerilir mi?","answer":"Evet, ancak portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131 ayr\u0131larak, dolar maliyet ortalamas\u0131 yaparak ve uzun vadeli d\u00fc\u015f\u00fcnerek yat\u0131r\u0131m yap\u0131lmas\u0131 \u00f6nerilir."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7e\u015fitli fonlama se\u00e7enekleri, kesirli hisse al\u0131m\u0131 ve e\u011fitim kaynaklar\u0131 sunmas\u0131 nedeniyle yeni yat\u0131r\u0131mc\u0131lar i\u00e7in caziptir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Intellia Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir arac\u0131 kurum veya ticaret platformu se\u00e7in, hesap a\u00e7\u0131n, fon yat\u0131r\u0131n, \"NTLA\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak hisse sat\u0131n al\u0131n ve portf\u00f6y\u00fcn\u00fcz\u00fc takip edin."},{"question":"Intellia Therapeutics hisseleri i\u00e7in riskler nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, d\u00fczenleyici onay engelleri, y\u00fcksek Ar-Ge maliyetleri, piyasa duyarl\u0131l\u0131\u011f\u0131 ve rekabet \u00f6nemli risk fakt\u00f6rleridir."},{"question":"Intellia Therapeutics'in 2025 sonras\u0131 fiyat tahmini nedir?","answer":"2025 sonunda 16-18 $, 2026'da 22-25 $, 2028'de 35-45 $ ve 2030'da 50-65 $ aral\u0131\u011f\u0131nda b\u00fcy\u00fcme beklenmektedir."},{"question":"Yeni ba\u015flayanlar i\u00e7in Intellia Therapeutics hissesi yat\u0131r\u0131m\u0131 \u00f6nerilir mi?","answer":"Evet, ancak portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131 ayr\u0131larak, dolar maliyet ortalamas\u0131 yaparak ve uzun vadeli d\u00fc\u015f\u00fcnerek yat\u0131r\u0131m yap\u0131lmas\u0131 \u00f6nerilir."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7e\u015fitli fonlama se\u00e7enekleri, kesirli hisse al\u0131m\u0131 ve e\u011fitim kaynaklar\u0131 sunmas\u0131 nedeniyle yeni yat\u0131r\u0131mc\u0131lar i\u00e7in caziptir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T10:19:59+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-20T10:19:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\",\"name\":\"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-20T10:19:59+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T10:19:59+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-20T10:19:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/","name":"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-20T10:19:59+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":340098,"slug":"how-to-buy-intellia-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Intellia Therapeutics, Inc. (NTLA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Intellia Therapeutics, Inc. (NTLA)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":340097,"slug":"how-to-buy-intellia-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Intellia Therapeutics, Inc. (NTLA) - Investimento em a\u00e7\u00f5es da Intellia Therapeutics, Inc. (NTLA)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/340102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=340102"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/340102\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=340102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=340102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=340102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}